Results 81 to 90 of about 1,087,549 (254)

Exploring the respiratory efficacy of combined chronic glucocorticoid and antioxidant interventions in the mdx mouse: The PREDNAC trial

Experimental Physiology, EarlyView.
Abstract Duchenne muscular dystrophy (DMD) is characterized by respiratory muscle injury and weakness, ultimately leading to respiratory failure. Impaired respiratory muscle performance, fibrosis and inflammation in early disease are evident in the dystrophin‐deficient mdx mouse model of DMD.
Michael N. Maxwell, Ben T. Murphy, Fiona B. McDonald, Ken D. O'Halloran   +3 more
wiley   +1 more source

Utrophin Compensates dystrophin Loss during Mouse Spermatogenesis

Scientific Reports, 2017
Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder resulting from mutations in the dystrophin gene. The mdx/utrn −/− mouse, lacking in both dystrophin and its autosomal homologue utrophin, is commonly used to model the clinical symptoms of
Hung-Chih Chen, Yu-Feng Chin, David J. Lundy, Chung-Tiang Liang, Ya-Hui Chi, Paolin Kuo, Patrick C. H. Hsieh   +6 more
doaj   +1 more source

Volitional exercise elicits physiological and molecular improvements in the severe D2.mdx mouse model of Duchenne muscular dystrophy

The Journal of Physiology, EarlyView.
Abstract figure legend This study investigated the effects of volitional exercise on muscle health in the more severe D2.mdx model of Duchenne muscular dystrophy (DMD). We showed that 8–10 weeks of a relatively high volume of voluntary wheel running (VWR) in D2.mdx animals augmented select muscle mass and normalized ex vivo muscle force compared to ...
Stephanie R. Mattina, Sean Y. Ng, Andrew I. Mikhail, Derek W. Stouth, Cora E. Jornacion, Irena A. Rebalka, Thomas J. Hawke, Vladimir Ljubicic   +7 more
wiley   +1 more source

In Vivo Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy

Molecular Therapy: Methods & Clinical Development, 2020
Delivery of therapeutic transgenes with adeno-associated viral (AAV) vectors for treatment of myopathies has yielded encouraging results in animal models and early clinical studies.
Jennifer B. Kwon, Adarsh R. Ettyreddy, Ashish Vankara, Joel D. Bohning, Garth Devlin, Stephen D. Hauschka, Aravind Asokan, Charles A. Gersbach   +7 more
doaj   +1 more source

Cathelicidin‐related antimicrobial peptide mediates skeletal muscle degeneration caused by injury and Duchenne muscular dystrophy in mice

Journal of Cachexia, Sarcopenia and Muscle, 2022
Background Cathelicidin, an antimicrobial peptide, plays a key role in regulating bacterial killing and innate immunity; however, its role in skeletal muscle function is unknown.
Moon‐Chang Choi, Jiwon Jo, Myeongjin Lee, Jonggwan Park, Tso‐Pang Yao, Yoonkyung Park   +5 more
doaj   +1 more source

Estrogen‐Related Receptor Alpha Promotes Skeletal Muscle Regeneration and Mitigates Muscular Dystrophy

The FASEB Journal, Volume 39, Issue 19, 15 October 2025.
ERRα promotes muscle regeneration. ERRα drives angiogenic and mitochondrial metabolic gene program in proliferating and differentiating myogenic cells. ERRα also induces myogenic factor genes such as MyoG. Through these pathways ERRα promotes muscle regeneration in the skeletal muscle in acute injury and chronic myopathy.
Thi Thu Hao Nguyen, Ya Xiang Huang, Svitlana Poliakova, Citu Citu, Eira Mann, Danesh H. Sopariwala, Zhongming Zhao, Ashok Kumar, Vihang A. Narkar   +8 more
wiley   +1 more source

Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone

Skeletal Muscle, 2018
BackgroundMyostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin antagonism with
A. Iskenderian, Nan Liu, Qingwei Deng, Yan Huang, Chuan Shen, Kathleen Palmieri, R. Crooker, Dianna M Lundberg, N. Kastrapeli, B. Pescatore, A. Romashko, John Dumas, Robert Comeau, Angela W. Norton, Jing Pan, H. Rong, K. Derakhchan, D. Ehmann   +17 more
semanticscholar   +1 more source

Filamented Light (FLight) Bioprinting of Mini‐Muscles with Self‐Renewal Potential

Advanced Materials, Volume 37, Issue 40, October 9, 2025.
This work presents the FLight biofabrication for engineering in vitro muscle constructs by photocrosslinking pristine collagen and fibrinogen using ruthenium. The resulting mini‐muscles retain in vivo‐like tissue organization and a Pax7⁺ cell pool.
Hao Liu, Michael Winkelbauer, Jakub Janiak, Patrick Weber, Ali Kerem Kalkan, Inseon Kim, Parth Chansoria, Ori Bar‐Nur, Marcy Zenobi‐Wong   +8 more
wiley   +1 more source

Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction‐induced loss of force‐producing capacity

Journal of Physiology, 2019
Adeno‐associated viral vector was used to elevate the expression of muscle specific kinase (MuSK) and rapsyn (a cytoplasmic MuSK effector protein) in the tibialis anterior muscle of wild‐type and dystrophic (mdx) mice. In mdx mice, enhanced expression of
S. Trajanovska, J. Ban, J. Huang, P. Gregorevic, M. Morsch, D. Allen, W. Phillips   +6 more
semanticscholar   +1 more source

Exosomal CCT6A Secreted by Cancer‐Associated Fibroblasts Interacts with β‐Catenin to Enhance Chemoresistance and Tumorigenesis in Gastric Cancer

Advanced Science, Volume 12, Issue 38, October 13, 2025.
Here, it is revealed that CAF‐secreted exosomal CCT6A enhances stemness, chemoresistance, and glycolysis in GC via the β‐catenin/c‐Myc/DDIT4‐TXNIP axis. Furthermore, CCT6P1, a pseudogene of CCT6A, is identified as upregulating CCT6A by competitively binding miR‐922, while c‐Myc transcriptionally activates both CCT6P1 and CCT6A.
Hui Sun, Tianqi Zhang, Xiaoyan Zhang, Yingxue Liu, Xu Wang, Xin Wang, Cong Tan, Shujuan Ni, Weiwei Weng, Meng Zhang, Lei Wang, Dan Huang, Xiaoyu Wang, Wenfeng Wang, Weiqi Sheng, Mi‐die Xu   +15 more
wiley   +1 more source